Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell–mediated cytotoxicity of multiple myeloma cells in preclinical studies. OBJECTIVE: A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evaluating teclistamab in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Girgis, Suzette, Lin, Shun Xin Wang, Pillarisetti, Kodandaram, Banerjee, Arnob, Stephenson, Tara, Ma, Xuewen, Shetty, Shoba, Yang, Tong-Yuan, Hilder, Brandi W., Jiao, Qun, Hanna, Brett, Adams, Homer C, Sun, Yu-Nien, Sharma, Amarnath, Smit, Jennifer, Infante, Jeffrey R., Goldberg, Jenna D., Elsayed, Yusri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345835/
https://www.ncbi.nlm.nih.gov/pubmed/35749004
http://dx.doi.org/10.1007/s11523-022-00893-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345835/
https://www.ncbi.nlm.nih.gov/pubmed/35749004
http://dx.doi.org/10.1007/s11523-022-00893-y

Ejemplares similares